Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 3
2006 2
2007 1
2008 2
2010 5
2011 4
2012 7
2013 1
2014 1
2015 5
2016 4
2017 3
2018 8
2019 10
2020 7
2021 13
2022 15
2023 9
2024 13
2025 9
2026 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

102 results

Results by year

Filters applied: . Clear all
Page 1
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
King B, Ohyama M, Kwon O, Zlotogorski A, Ko J, Mesinkovska NA, Hordinsky M, Dutronc Y, Wu WS, McCollam J, Chiasserini C, Yu G, Stanley S, Holzwarth K, DeLozier AM, Sinclair R; BRAVE-AA Investigators. King B, et al. N Engl J Med. 2022 May 5;386(18):1687-1699. doi: 10.1056/NEJMoa2110343. Epub 2022 Mar 26. N Engl J Med. 2022. PMID: 35334197 Clinical Trial.
Psoriasis.
Armstrong AW, Blauvelt A, Callis Duffin K, Huang YH, Savage LJ, Guo L, Merola JF. Armstrong AW, et al. Among authors: huang yh. Nat Rev Dis Primers. 2025 Jun 26;11(1):45. doi: 10.1038/s41572-025-00630-5. Nat Rev Dis Primers. 2025. PMID: 40571687 Review.
Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites.
Gooderham M, Lain E, Bissonnette R, Huang YH, Lynde CW, Hoffmann M, Song EJ, Weirich O, Ceitlin RHG, Rubens JH, DeLozier AM, Ota T, Hsu MC, Li S, DeKlotz CMC, Nunes F, Warren RB. Gooderham M, et al. Among authors: huang yh. NEJM Evid. 2025 Dec;4(12):EVIDoa2500155. doi: 10.1056/EVIDoa2500155. Epub 2025 Nov 5. NEJM Evid. 2025. PMID: 41191932 Clinical Trial.
Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Nash P, Kirkham B, Okada M, Rahman P, Combe B, Burmester GR, Adams DH, Kerr L, Lee C, Shuler CL, Genovese M; SPIRIT-P2 Study Group. Nash P, et al. Lancet. 2017 Jun 10;389(10086):2317-2327. doi: 10.1016/S0140-6736(17)31429-0. Epub 2017 May 24. Lancet. 2017. PMID: 28551073 Clinical Trial.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
Indirect comparison of deucravacitinib and other systemic treatments for moderate to severe plaque psoriasis in Asian populations: A systematic literature review and network meta-analysis.
Tsai TF, Tada Y, Kung C, Zhong Y, Cichewicz A, Borkowska K, Westley T, Kisa RM, Huang YH, Gao XH, Jo SJ, Armstrong AW. Tsai TF, et al. Among authors: huang yh. J Dermatol. 2024 Dec;51(12):1559-1571. doi: 10.1111/1346-8138.17448. Epub 2024 Nov 11. J Dermatol. 2024. PMID: 39526612 Free PMC article.
Population-specific polygenic risk scores for people of Han Chinese ancestry.
Chen HH, Chen CH, Hou MC, Fu YC, Li LH, Chou CY, Yeh EC, Tsai MF, Chen CH, Yang HC, Huang YT, Liu YM, Wei CY, Su JP, Lin WJ, Wang EHF, Chiang CL, Jiang JK, Lee IH, Liang KH, Chen WS, Tsai HC, Lin SY, Chang FP, Ho HL, Yeh YC, Tseng WC, Lin MH, Chang HT, Tseng LM, Liang WY, Chen PC, Hsieh YC, Chen YM, Hsiao TH, Lin CH, Chen YJ, Chen IC, Mao CL, Chang SJ, Chang YL, Liao YJ, Lai CH, Lee WJ, Tung H, Yen TT, Yen HC, Chen MY, Lin YC, Kao YT, Kao BZ, Lee JE, Chung CL, Liu JC, Chan P, Lin CH, Chen CH, Wu IC, Lin LC, Wang JW, Shih SL, Hsieh SW, Hung CH, Li WM, Yang CJ, Yang CS, Weng RH, Chen YC, Chang CP, Wu TH, Lin YC, Sheen YJ, Wang SH, Chen SP, Raben T, Widen E, Hsu S, Hsieh FJ, Ho DR, Huang YH, Yang CH, Huang YS, Chen YF, Wu HM, Tsai PH, Huang KG, Chien CY, Ho YL, Wu MS, Kao JH, Liu YB, Juang JJ, Lin MH, Lin YH, Lee JY, Lu HJ, Lu CH, Feng AC, Liu JS, Chiang CP, Chu NF, Lin JC, Yeh YW, Meng E, Huang CY, Li CC, Wang TF, Su KY, Wang JK, Chen MH, Chen HF, Ma GC, Chang TY, Chiang FT, Chang HJ, Kao KJ, Hung CF, Tsai CY, Chen PY, Tsui K, Chen YT, Kwok PY, Sheu WH, Yang SF, Liou JM, Wang JY, Chiou JF, Wu JY, Fann CSJ. Chen HH, et al. Among authors: huang yh. Nature. 2025 Dec;648(8092):128-137. doi: 10.1038/s41586-025-09350-y. Epub 2025 Oct 15. Nature. 2025. PMID: 41094136 Free PMC article.
FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis.
Ferris LK, Bagel J, Huang YH, Pink AE, Tyring SK, Kokolakis G, DeLozier AM, Li S, Shen YK, Iaconangelo C, Ota T, Bissonnette R. Ferris LK, et al. Among authors: huang yh. J Am Acad Dermatol. 2025 Mar;92(3):495-502. doi: 10.1016/j.jaad.2024.10.076. Epub 2024 Nov 14. J Am Acad Dermatol. 2025. PMID: 39549848 Free article. Clinical Trial.
102 results